RCS - Theracryf PLC - European Patent Office award decision

TheracryfAnnouncement

27/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241127:nRSa7653Na&default-theme=true

RNS Number : 7653N  Theracryf PLC  27 November 2024

RNS REACH

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

European Patent Office decision to award patent for Ox-1 antagonist

 

Alderley Park, UK - 27 November 2024: TheraCryf plc (AIM: TCF), the clinical
stage drug development company focussing on oncology and neuropsychiatry has
received the decision from the European Patent Office to award a Composition
of Matter patent for its Orexin 1 (Ox-1) receptor antagonist in Europe, with a
formal grant to be made on 18 December 2024.

TheraCryf's highly selective Ox-1 receptor antagonist was acquired as part of
its acquisition of Chronos Therapeutics Ltd in April 2024.  An imbalance in
Orexin production and stimulation of the Orexin 1 receptor in the brain has
been linked to anxiety, addiction and other  mental health conditions. An
Orexin 1 receptor antagonist inhibits the effect of Orexin on this receptor,
potentially providing effective treatments for these disorders. TheraCryf's
Ox-1 is the most selective Orexin 1  receptor antagonist thus far discovered
and is currently at late pre-clinical stage.

This patent adds to TheraCryf's extensive international IP portfolio covering
its oncology and neuropsychiatry products.

Dr Huw Jones, TheraCryf's CEO, commented:

"Composition of Matter patents such as this are the strongest form of
intellectual property available. This decision will give extensive protection
for our candidate Ox-1 receptor antagonist and associated novel molecular
structures in the broad group of territories covered by the European Patent
Office, complementing the patents in this family already awarded  in the USA
and Asia."

-Ends-

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD and Broker)                +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Vigo Consulting                                             +44 (0)20 7390 0231
 Rozi Morris
theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C:/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABFBBTMTJTTMI